Inaphaea Evaluation and Commercial Use Agreement

ValiRx PLC

27 August 2024

 

ValiRx plc

("ValiRx" or the "Company")

Inaphaea Evaluation and Commercial Use Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of an Evaluation and Commercial Use agreement ("Agreement") with Swedish contract research organisation BioReperia AB ("BioReperia") to provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and commercial use in BioReperia's unique in-vivo ZTX® platform.  The contract initially focusses on establishment of up to four glioblastoma zebrafish xenografts which will then be offered for commercial services by BioReperia. Additional PDCs across Inaphaea's range of 66 cancer types can be added at any time.

Inaphaea will be entitled to an upfront fee and a percentage of service royalties on commercialisation of the models. Both companies have also agreed to co-market their respective services. The Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented "It's great to be working with an innovative partner like BioReperia to extend the applications of the PDCs from our biobank. Inaphaea can now offer its clients a seamless route from in-vitro into in-vivo drug development."

Mark Eccleston, CEO of ValiRx commented "This deal represents a great step forward in commercialising Inaphaea's primary asset - its Patient Derived Cell bank. Productising Inaphaea's cell bank is a key strategic objective."

Anna Erkstam, CEO of Bioreperia, commented "We are very excited to partner with Inaphaea. As an in-vivo service provider, it is very important that the tumour models that we use are recapitulating the patient specific environment to be able to evaluate new cancer treatments in relevant models. The collaboration enables us to expand our clinical model repertoire for our customers and merge the unique profile of Inaphaea´s models with our cutting edge in-vivo model. This creates a powerful tool for drug developers to evaluate their new compounds in a translational and biologically relevant platform."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

ValiRx plc Dr Mark Eccleston, CEO	Tel: [phone] www.valirx.com [e-mail]
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	[phone] www.vformation.biz [e-mail] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	Tel: [phone]
Shard Capital Partners LLP (Sole Broker) Damon Heath	Tel: [phone]

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

END